JP2023516225A5 - - Google Patents
Info
- Publication number
- JP2023516225A5 JP2023516225A5 JP2022564251A JP2022564251A JP2023516225A5 JP 2023516225 A5 JP2023516225 A5 JP 2023516225A5 JP 2022564251 A JP2022564251 A JP 2022564251A JP 2022564251 A JP2022564251 A JP 2022564251A JP 2023516225 A5 JP2023516225 A5 JP 2023516225A5
- Authority
- JP
- Japan
- Prior art keywords
- genome editing
- editing complex
- complex according
- cell
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025155380A JP2026005238A (ja) | 2020-04-24 | 2025-09-18 | Ｋｒａｓ突然変異を有するがんを処置するための組成物およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2004126 | 2020-04-24 | ||
| FR2004126 | 2020-04-24 | ||
| PCT/US2021/028995 WO2021217100A1 (en) | 2020-04-24 | 2021-04-23 | Compositions for treating cancer with kras mutations and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025155380A Division JP2026005238A (ja) | 2020-04-24 | 2025-09-18 | Ｋｒａｓ突然変異を有するがんを処置するための組成物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023516225A JP2023516225A (ja) | 2023-04-18 |
| JP2023516225A5 true JP2023516225A5 (enExample) | 2024-05-07 |
Family
ID=78270082
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564251A Withdrawn JP2023516225A (ja) | 2020-04-24 | 2021-04-23 | Ｋｒａｓ突然変異を有するがんを処置するための組成物およびその使用 |
| JP2025155380A Pending JP2026005238A (ja) | 2020-04-24 | 2025-09-18 | Ｋｒａｓ突然変異を有するがんを処置するための組成物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025155380A Pending JP2026005238A (ja) | 2020-04-24 | 2025-09-18 | Ｋｒａｓ突然変異を有するがんを処置するための組成物およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230167437A1 (enExample) |
| EP (1) | EP4139454A4 (enExample) |
| JP (2) | JP2023516225A (enExample) |
| CN (1) | CN115916973A (enExample) |
| AU (1) | AU2021261423A1 (enExample) |
| CA (1) | CA3181170A1 (enExample) |
| MX (1) | MX2022013362A (enExample) |
| WO (1) | WO2021217100A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020214846A1 (en) | 2019-04-17 | 2020-10-22 | Aadigen, Llc | Peptides and nanoparticles for intracellular delivery of molecules |
| US20250228953A1 (en) * | 2021-11-08 | 2025-07-17 | Entrada Therapeutics, Inc. | Intracellular targeting of oligonucleotides |
| WO2023114887A2 (en) * | 2021-12-15 | 2023-06-22 | The Trustees Of Indiana University | Cell targeting compositions and methods |
| JP2023176123A (ja) * | 2022-05-31 | 2023-12-13 | 株式会社 光バイオ | ウイルスベクター及びそれを含むがん細胞増殖抑制剤 |
| CN119384498A (zh) * | 2022-06-16 | 2025-01-28 | 因特利亚治疗公司 | 用于对细胞进行遗传修饰的方法和组合物 |
| WO2024187174A2 (en) | 2023-03-09 | 2024-09-12 | Aadigen, Llc | Compositions for treating cancer with kras mutations and uses thereof |
| EP4777526A1 (en) * | 2023-09-12 | 2026-07-22 | Aadigen, LLC | Methods and compositions for treating or preventing cancer |
| WO2025193628A2 (en) | 2024-03-09 | 2025-09-18 | Aadigen, Llc | Compositions for treating cancer with kras mutations and uses thereof |
| CN120005043B (zh) * | 2025-02-17 | 2026-07-17 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | 一种用于抑制PRDX1 O-GlcNAc修饰的短肽及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100666099B1 (ko) * | 2004-04-27 | 2007-01-10 | 국립암센터 | Ｋ―ｒａｓ 올리고뉴클레오티드 마이크로어레이 및 이를이용하여 Ｋ―ｒａｓ 유전자의 돌연변이를 검사하는 방법 |
| US8889642B2 (en) * | 2012-04-19 | 2014-11-18 | Silenseed Ltd. | Methods and compositions for RNAi-based cancer treatment |
| WO2016049024A2 (en) * | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
| CA3025523A1 (en) * | 2016-05-27 | 2017-11-30 | Aadigen, Llc | Peptides and nanoparticles for intracellular delivery of genome-editing molecules |
| KR20190039115A (ko) * | 2016-07-05 | 2019-04-10 | 더 존스 홉킨스 유니버시티 | 암을 치료하기 위한 crispr/cas9-기반 조성물 및 방법 |
| KR101997116B1 (ko) * | 2016-10-14 | 2019-07-05 | 연세대학교 산학협력단 | Kras 유전자에 상보적인 가이드 rna 및 이의 용도 |
| KR101796036B1 (ko) * | 2016-12-29 | 2017-11-10 | 주식회사 무진메디 | Cas9 단백질, KRAS 유전자의 발현을 억제하는 가이드 RNA 및 양이온성 폴리머의 복합체가 봉입된 나노 리포좀 전달체 조성물 또는 이를 함유하는 KRAS 유전자 변이에 따른 항암제 저항성 대장암 치료제 |
| JP2020530463A (ja) * | 2017-08-10 | 2020-10-22 | アーディジェン， エルエルシー | ウイルスの細胞内送達のためのペプチドおよびナノ粒子 |
| JP7395483B2 (ja) * | 2017-10-16 | 2023-12-11 | アーディジェン， エルエルシー | ｍＲＮＡの細胞内送達のためのペプチドおよびナノ粒子 |
| CA3104989A1 (en) * | 2018-03-27 | 2019-10-03 | G+Flas Life Sciences | Sequence-specific in vivo cell targeting |
-
2021
- 2021-04-23 US US17/920,355 patent/US20230167437A1/en active Pending
- 2021-04-23 CA CA3181170A patent/CA3181170A1/en active Pending
- 2021-04-23 JP JP2022564251A patent/JP2023516225A/ja not_active Withdrawn
- 2021-04-23 CN CN202180044035.3A patent/CN115916973A/zh active Pending
- 2021-04-23 WO PCT/US2021/028995 patent/WO2021217100A1/en not_active Ceased
- 2021-04-23 EP EP21791810.1A patent/EP4139454A4/en active Pending
- 2021-04-23 MX MX2022013362A patent/MX2022013362A/es unknown
- 2021-04-23 AU AU2021261423A patent/AU2021261423A1/en active Pending
-
2025
- 2025-09-18 JP JP2025155380A patent/JP2026005238A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Quijano et al. | Therapeutic peptide nucleic acids: principles, limitations, and opportunities | |
| Angell et al. | DNA nanotechnology for precise control over drug delivery and gene therapy | |
| ES2959815T3 (es) | Edición génica selectiva de alelo y usos de la misma | |
| US20230167437A1 (en) | Compositions for treating cancer with kras mutations and uses thereof | |
| JP2024541962A5 (enExample) | ||
| JP7715638B2 (ja) | 分子を細胞内送達するためのペプチドおよびナノ粒子 | |
| CN110507817B (zh) | 一种dna纳米疫苗及其制备方法和应用 | |
| JP5906327B2 (ja) | 磁性ナノ粒子−ＳＡＭｉＲＮＡ複合体およびその製造方法 | |
| JP2018504896A5 (enExample) | ||
| WO2019126037A1 (en) | Modified tracrrnas grnas, and uses thereof | |
| US20070161587A1 (en) | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof | |
| Wang et al. | Metal ion assisted interface re-engineering of a ferritin nanocage for enhanced biofunctions and cancer therapy | |
| EP3784252A1 (en) | Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell | |
| AU2019378108A1 (en) | Extracellular vesicles for replacement of urea cycle proteins and nucleic acids | |
| JP2024518100A5 (enExample) | ||
| JP2025522366A (ja) | 非ウイルス性送達組成物およびスクリーニング方法 | |
| JP2016513089A (ja) | 細胞への遺伝子送達のための機能性ｄｎａデンドリマー | |
| WO2024231575A1 (en) | Improved crispr/cas guide rna (grna) | |
| WO2003025139A2 (en) | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof | |
| JP2003519241A (ja) | 二層型鉱物粒子に取り込まれた核酸を含む組成物 | |
| JP2023526328A5 (enExample) | ||
| CN118043461A (zh) | 方法 | |
| WO2022243484A1 (en) | Nanoparticle delivery system for production of engineered extracellular vesicles | |
| CN120154740A (zh) | CRISPR/dCas9-SunTag介导的RBM25可控激活系统及其在缺血性心衰心肌修复中的应用 | |
| CA3158437A1 (en) | Nanoparticle-like delivery system |